The global Acute Kidney Injury Treatment Market is expected to witness staggering growth, registering an 8.2% CAGR during the forecast period (2022 to 2029). The overall demand for acute kidney injury treatment is expected to surpass a valuation of US$ 2,058.2 Million in 2022 and is projected to reach US$ 3,566.7 Million by the end of 2029.
| Attribute | Details |
|---|---|
| Acute Kidney Injury Treatment Market Size Value in 2014 | US$ 1,177.7 Million |
| Acute Kidney Injury Treatment Market Size Value in 2029 | US$ 3,566.7 Million |
| Acute Kidney Injury Treatment Market Historical CAGR (2014 to 2021) | 7.1% |
| Acute Kidney Injury Treatment Market CAGR (2022 to 2029) | 8.2% |
The rising incidence of acute kidney injuries and the increasing rate of dialysis therapies are primary factors driving the acute kidney injury treatment market. Besides this, growing awareness regarding the early prognosis of this injury will also fuel the demand for acute kidney injury treatment worldwide.
Regionally, North America is anticipated to account for the largest share of the global acute kidney injury treatment market. As per the study, over 40.8% of acute kidney injury treatment sales are expected to concentrate in North America through 2022.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 8.11% |
| H1, 2022 Projected | 8.17% |
| H1, 2022 Outlook | 6.97% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 120 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 114 ↓ |
The H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 120 BPS. In H1-2022, the growth rate of the acute kidney injury treatment market is expected to fall by 114 basis point shares (BPS), as per FMI analysis.
The market shows a decline in the BPS values, owing to the substantial inpatient costs incurred by patients with acute kidney injury (AKI). Moreover, patients with dialysis requirements experience a greater burden associated with healthcare costs due to longer hospitalization. The substantial difference in pricing for acute kidney injury treatment and care in hospital settings has thus resulted in a drop in the BPS values.
The market is influenced by several macro and industrial dynamics, such as disease prevalence, and target population group demography. The key developments in this market include the advancements in the current understanding of renal injury and repair signaling for better management of AKI.
Conversely, the development of novel biomarkers which aid with the differentiation of AKI from Acute tubular necrosis (ATN), has presented opportunities for enhanced disease diagnosis, identification, and management, thus providing a positive outlook towards market growth.
As per Future Market Insights (FMI), the global acute kidney injury treatment market grew at 7.1% CAGR between 2014 and 2021. The demand for acute kidney injury treatment is expected to increase two-fold, exceeding US$ 1,897.7 Million through 2021 & beyond.
Advancements in diagnostic technology and growing cases of acute kidney injuries are expected to bolster the growth in the market. With increasing kidney-related disorders across the globe, the number of dialysis centers has surged worldwide.
As the rate of acute kidney injury cases is increasing, patients are actively seeking advanced acute renal disease treatment. On account of this, healthcare professionals are adopting advanced diagnostic equipment to enhance the detection of disease and improve the care of patients.
Besides this, the growing adoption of advanced treatment across emerging economies such as India, Japan, and China is propelling growth in the East and South Asia markets. Backed by these aforementioned factors, the global acute injury treatment market is poised to expand at 8.2% CAGR between 2022 and 2029, surpassing US$ 2,237.2 Million by the end of 2023.
Principal Consultant
The advent of Tech-Driven AKI Treatment to Drive the Acute Kidney Injury Treatment Market
According to the International Society of Nephrology (ISN), around 13.3 million people suffer from acute kidney injury (AKI). Among these, nearly 11.3 million cases are from emerging economies such as India, China, Africa, and Japan.
Out of 1.7 million deaths globally every year due to AKI, around 1.4 million occur in low- and middle-income economies. To reduce the global burden of acute renal diseases and kidney injuries, the demand for advanced diagnostic treatment is increasing.
Conventional dialysis systems require manual adjustments for every individual and parameter. However, with the advancements in technology and integration of artificial intelligence in AKI stage 1 treatment, automated dialysis treatment is delivering enhanced care to patients.
These new-age dialysis machines enable all the parameters automatically, minimizing human intervention. Moreover, key players are improving the efficiency of dialysis, including the usage of high-flux and high-efficacy membranes, emanating from technical advances.
This is expected to boost the global acute kidney injury treatment market over the forecast period (2022 to 2029).
High-Cost Associated with AKI Treatment Equipment Might Impede the Sales
While new product development and the introduction of portable, automated AKI equipment favoring growth in developed economies, high-cost associated with this equipment might impede sales in low-income countries.
Besides this, the lack of early disease detection and awareness regarding kidney-related diseases and acute kidney injuries in emerging economies will also hamper the growth of the market.
However, governments in countries such as India and China are introducing reimbursement policies to offer treatment at a low cost. Some private healthcare organizations are also undertaking several initiatives and projects to increase awareness regarding AKI.
This is expected to aid the growth of the acute kidney injury treatment market, especially across the Asia Pacific and Latin America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Rising Awareness for Acute Renal Disease Treatment to Augment Growth
As per Future Market Insights, North America is expected to dominate the market, with the USA leading the growth in North America. Primary factors underpinning the growth in the market include the rising prevalence of kidney-related disorders and rapid development in diagnostic equipment.
According to the research, nearly 786,000 people are living with kidney-related disorders in the USA Among 1000 persons 55 of them are hospitalized with severe acute kidney injury diagnoses. Out of which 5% succumb to the disease every year, states medical research in the USA
With rising awareness regarding acute renal disease treatment, the development of advanced and automated AKI diagnostic equipment is surging in the USA Several private healthcare organizations are increasing the adoption of advanced AKI equipment to enhance the care to the patients.
On account of this, several leading players are eyeing the USA market to increase their revenue through product development and new launches in the country. A slew of such developments by key players are expected to bolster the growth in the USA market.
Surging Prevalence of AKI to Increase the Demand for Acute Kidney Diseases Treatment
According to the ISN, nearly 1.4 million succumb to acute kidney injuries in low and middle-income countries, among which the majority of the cases are recorded in India. Due to the rising prevalence of AKI, the number of dialysis centers has surged in the country.
With the establishment of these centers, the adoption of AKI treatment equipment is increasing among healthcare professionals. Additionally, rapid technological advancements in healthcare infrastructure and favorable government policies are also improving the adoption of advanced AKI equipment and diagnostic treatment.
Also, increasing awareness regarding the treatment for acute kidney disease is expected to boost the sales of AKI treatment diagnostic equipment in these dialysis centers. Subsequently, rising disposable income and growing health consciousness have enabled patients to opt for advanced treatment for these diseases.
Backed by these aforementioned factors, key players aiming for novel product development and launches in India. This is expected to create a conducive environment for the acute kidney injury treatment market in India.
Influenced by Well-Established Healthcare Infrastructure, China AKI Treatment Market is Set to Gain Traction
China is one of the fastest-growing markets for acute kidney injury treatment. Growth in the country is attributable to the rising incidence of kidney-related diseases and the expansion of the healthcare industry.
With the growing prevalence of pre-renal injuries in China, the rate of hospitalization, especially for the geriatric population has increased. Hence, the adoption of dialysis equipment and drug-induced therapies has surged in China’s healthcare industry.
Also, the government in China is adopting various initiatives and introducing projects to create awareness regarding AKI and kidney-related diseases.
For instance, in 2017, China’s central government issued the 13th Five-Year National Science and Technology Innovation Plan, which aims to create a national platform to share biomedical big data
The expansion of the healthcare industry and the adoption of automated diagnostic equipment is favoring the growth in the China market. On the back of developing the healthcare industry, key players are streamlining their projects and introducing new products in China.
Such factors are projected to propel the growth in China's acute kidney injury treatment market over the forecast period.
Dialysis and Pre-Renal Injury to Account for Maximum Share in Acute Kidney Injury Treatment Market
In terms of product type, the dialysis segment is expected to account for the maximum revenue share during the forecast period. With the growing prevalence of acute kidney injury, the establishment of dialysis centers across the globe has increased.
As per Future Market Insights, dialysis is expected to remain the most preferred and efficient treatment for AKI. Around 9 out of 10 healthcare professionals suggest and opt for dialysis. As intermittent hemodialysis has excellent efficiency, patients are actively seeking this treatment.
Consequently, governments in emerging economies are establishing an increasing number of dialysis centers. Besides this, the growing prevalence of pre-renal injury is also aiding the growth of the dialysis segment.
In terms of injury type, the pre-renal injury segment is expected to contribute over 60.7% of sales in the acute kidney injury treatment market, as it covers the maximum patient population.
Hospitals to Contribute over 50% of Global Acute Kidney Injury Treatment Market Sales
In terms of distribution channels, hospitals are expected to gain the maximum share of the acute kidney injury treatment market. According to FMI, over 80% of sales in the market are contributed by hospitals and ambulatory surgical centers, collectively.
However, with well-established infrastructure and the availability of diagnostic equipment in hospitals, governments in several countries are increasing the supply of AKI treatment equipment in hospitals.
Hospitals in several low and middle-income countries are receiving equipment under the initiative of developing healthcare infrastructure by the government and private organizations.
For instance, according to the India Brand Equity Foundation, in 2021, the Ministry of AYUSH was allocated US$ 407.84 million to develop the healthcare infrastructure. By 2025, with favorable investment Government of India is planning to increase public health spending by 2.5% of the country’s GDP.
Leading players in the global acute kidney injury treatment market are focusing on developing automated, portable, and tech-driven dialysis equipment to deliver advanced care to patients. They are also integrating advanced technologies such as artificial intelligence and the Internet of Things (IoT) to expand their product portfolio.
Meanwhile, some of the other players are making advancements in diagnostic technology in order to streamline their product offerings in emerging economies with diverse product portfolios.
For instance:
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2029 |
| Historical Data Available for | 2014 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East and Africa(MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, and others. |
| Key Market Segments Covered | Product, Injury, Distribution Channel, and Region |
| Key Companies Profiled | Novartis, Pfizer Inc.;Merck & Co.; Biocon Ltd.; Teva Pharmaceutical Industries Ltd.; Mylan Pharmaceuticals Inc.; NIPRO Medical; Baxter Corporation; Asahi Kasei; NIKKISO; Fresenius Medical Care; Others |
| Pricing | Available upon Request |
1. Executive Summary | Acute Kidney Injury Treatment Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition
3. Key Market Trends
3.1. Key Trends Impacting the Market
4. Key Success Factors
4.1. Pipeline Assessment
4.2. Unmet needs
5. Global Market Demand (in Value or Size in US$ Million) Analysis 2014 to 2021 and Forecast, 2022 to 2029
5.1. Historical Market Value (US$ Million) Analysis, 2014 to 2021
5.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2029
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global GDP Growth Outlook
6.1.2. Global Healthcare Spending Outlook
6.2. Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Opportunity Analysis
7. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Injury
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Analysis By Injury, 2014 to 2021
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Injury, 2022 to 2029
7.3.1. Pre-renal Injury
7.3.2. Intrinsic Renal Injury
7.3.3. Post-renal Injury
7.4. Market Attractiveness Analysis By Injury
8. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Therapy, 2014 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Therapy, 2022 to 2029
8.3.1. Drug Therapy
8.3.1.1. Isotonic Solutions
8.3.1.2. Antibiotics
8.3.1.3. Diuretics
8.3.1.4. Immunosuppressive agents
8.3.2. Dialysis
8.3.2.1. Intermittent Hemodialysis
8.3.2.2. Continuous Renal Replacement Therapy (CRRT)
8.3.2.3. Sustained Low-Efficiency Dialysis (SLED)
8.4. Market Attractiveness Analysis By Therapy
9. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Sales Channels, 2014 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2029
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Others Market Attractiveness Analysis By Distribution Channel
10. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Million) Analysis By Region, 2014 to 2021
10.3. Current Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2029
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. South Asia
10.3.5. East Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021
11.3. Market Size (US$ Million) and Volume Forecast By Market Taxonomy, 2022 to 2029
11.3.1. By Country
11.3.1.1. USA
11.3.1.2. Canada
11.3.2. By Injury
11.3.3. By Therapy
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Injury
11.4.3. By Therapy
11.4.4. By Distribution Channel
11.5. Drivers and Restraints - Impact Analysis
12. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021
12.3. Market Size (US$ Million) and Volume Forecast By Market Taxonomy, 2022 to 2029
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Argentina
12.3.1.3. Mexico
12.3.1.4. Rest of Latin America
12.3.2. By Injury
12.3.3. By Therapy
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Injury
12.4.3. By Therapy
12.4.4. By Distribution Channel
12.5. Drivers and Restraints - Impact Analysis
13. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021
13.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. United Kingdom
13.3.1.3. France
13.3.1.4. France
13.3.1.5. Italy
13.3.1.6. Spain
13.3.1.7. Russia
13.3.1.8. Rest of Europe
13.3.2. By Injury
13.3.3. By Therapy
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Injury
13.4.3. By Therapy
13.4.4. By Distribution Channel
13.5. Drivers and Restraints - Impact Analysis
14. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
14.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Thailand
14.3.1.3. Indonesia
14.3.1.4. Malaysia
14.3.1.5. Rest of South Asia
14.3.2. By Injury
14.3.3. By Therapy
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Injury
14.4.3. By Therapy
14.4.4. By Distribution Channel
14.5. Drivers and Restraints - Impact Analysis
15. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029
15.1. Introduction
15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2014 to 2021
15.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Injury
15.3.3. By Therapy
15.3.4. By Sales Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Injury
15.4.3. By Therapy
15.4.4. By Distribution Channel
15.5. Drivers and Restraints - Impact Analysis
16. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021
16.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Injury
16.3.3. By Therapy
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Injury
16.4.3. By Therapy
16.4.4. By Distribution Channel
16.5. Drivers and Restraints - Impact Analysis
17. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2014 to 2021
17.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2029
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Turkey
17.3.1.3. Northern Africa
17.3.1.4. South Africa
17.3.1.5. Rest of Middle East and Africa
17.3.2. By Injury
17.3.3. By Therapy
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Injury
17.4.3. By Therapy
17.4.4. By Distribution Channel
17.5. Drivers and Restraints - Impact Analysis
18. Emerging Countries Market Analysis 2014 to 2021 and Forecast 2022 to 2029
18.1. Introduction
18.1.1. Market Value Proportion Analysis, By Key Countries
18.1.2. Global Vs. Country Growth Comparison
18.2. China Market Analysis
18.2.1. Introduction
18.2.2. Market Value Proportion Analysis by Market Taxonomy
18.2.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy
18.2.3.1. By Injury
18.2.3.2. By Therapy
18.2.3.3. By Distribution Channel
18.2.4. China Market - Competition Landscape
18.3. India Market Analysis
18.3.1. Introduction
18.3.2. Market Value Proportion Analysis by Market Taxonomy
18.3.3. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy
18.3.3.1. By Injury
18.3.3.2. By Therapy
18.3.3.3. By Distribution Channel
18.3.4. India Market - Competition Landscape
18.4. Brazil Market Analysis
18.4.1. Introduction
18.4.2. Pricing Analysis
18.4.3. PEST Analysis
18.4.4. Market Value Proportion Analysis by Market Taxonomy
18.4.5. Market Value (US$ Million) Analysis and Forecast by Market Taxonomy
18.4.5.1. By Injury
18.4.5.2. By Therapy
18.4.5.3. By Distribution Channel
18.4.6. Brazil Market - Competition Landscape
19. Key Countries Analysis
19.1. USA Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.1.1. Introduction
19.1.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.1.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.1.3.1. By Injury
19.1.3.2. By Therapy
19.1.3.3. By Distribution Channel
19.1.4. Market Attractiveness Analysis
19.2. Canada Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.2.1. Introduction
19.2.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.2.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.2.3.1. By Injury
19.2.3.2. By Therapy
19.2.3.3. By Distribution Channel
19.2.4. Market Attractiveness Analysis
19.3. Germany Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.3.1. Introduction
19.3.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.3.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.3.3.1. By Injury
19.3.3.2. By Therapy
19.3.3.3. By Distribution Channel
19.3.4. Market Attractiveness Analysis
19.4. United Kingdom Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.4.1. Introduction
19.4.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.4.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.4.3.1. By Injury
19.4.3.2. By Therapy
19.4.3.3. By Distribution Channel
19.4.4. Market Attractiveness Analysis
19.5. France Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.5.1. Introduction
19.5.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.5.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.5.3.1. By Injury
19.5.3.2. By Therapy
19.5.3.3. By Distribution Channel
19.5.4. Market Attractiveness Analysis
19.6. Italy Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.6.1. Introduction
19.6.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.6.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.6.3.1. By Injury
19.6.3.2. By Therapy
19.6.3.3. By Distribution Channel
19.6.4. Market Attractiveness Analysis
19.7. Spain Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.7.1. Introduction
19.7.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.7.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.7.3.1. By Injury
19.7.3.2. By Therapy
19.7.3.3. By Distribution Channel
19.7.4. Market Attractiveness Analysis
19.8. Russia Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.8.1. Introduction
19.8.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.8.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.8.3.1. By Injury
19.8.3.2. By Therapy
19.8.3.3. By Distribution Channel
19.8.4. Market Attractiveness Analysis
19.9. Japan Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.9.1. Introduction
19.9.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.9.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.9.3.1. By Injury
19.9.3.2. By Therapy
19.9.3.3. By Distribution Channel
19.9.4. Market Attractiveness Analysis
19.10. South Korea Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.10.1. Introduction
19.10.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.10.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.10.3.1. By Injury
19.10.3.2. By Therapy
19.10.3.3. By Distribution Channel
19.10.4. Market Attractiveness Analysis
19.11. Australia Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.11.1. Introduction
19.11.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.11.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.11.3.1. By Injury
19.11.3.2. By Therapy
19.11.3.3. By Distribution Channel
19.11.4. Market Attractiveness Analysis
19.12. South Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.12.1. Introduction
19.12.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.12.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.12.3.1. By Injury
19.12.3.2. By Therapy
19.12.3.3. By Distribution Channel
19.12.4. Market Attractiveness Analysis
19.13. GCC Countries Market Analysis 2014 to 2021 and Forecast 2022 to 2029
19.13.1. Introduction
19.13.2. Historical Market Size (US$ Million) & Volume Units Trend Analysis By Market Taxonomy, 2014 to 2021
19.13.3. Market Size (US$ Million) & Volume Units Forecast By Market Taxonomy, 2022 to 2029
19.13.3.1. By Injury
19.13.3.2. By Therapy
19.13.3.3. By Distribution Channel
19.13.4. Market Attractiveness Analysis
20. Market Structure Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Novartis
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.1.5.1. Promotional Strategy
21.3.1.5.2. Product Strategy
21.3.2. Pfizer Inc.
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.2.5.1. Promotional Strategy
21.3.2.5.2. Product Strategy
21.3.3. Merck & Co.
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.3.5.1. Promotional Strategy
21.3.3.5.2. Product Strategy
21.3.4. Biocon Ltd.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.4.5.1. Promotional Strategy
21.3.4.5.2. Product Strategy
21.3.5. Teva Pharmaceutical Industries Ltd.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.5.5.1. Promotional Strategy
21.3.5.5.2. Product Strategy
21.3.6. Mylan Pharmaceuticals Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.6.5.1. Promotional Strategy
21.3.6.5.2. Product Strategy
21.3.7. NIPRO Medical
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.7.5.1. Promotional Strategy
21.3.7.5.2. Product Strategy
21.3.8. Baxter Corporation
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.8.5.1. Promotional Strategy
21.3.8.5.2. Product Strategy
21.3.9. Asahi Kasei
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
21.3.9.5.1. Promotional Strategy
21.3.9.5.2. Product Strategy
21.3.10. NIKKISO
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Strategy Overview
21.3.10.5.1. Promotional Strategy
21.3.10.5.2. Product Strategy
21.3.11. Fresenius Medical Care
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Strategy Overview
21.3.11.5.1. Promotional Strategy
21.3.11.5.2. Product Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Acute Kidney Injury Treatment Market
